Randomized, placebo-controlled, single-Ascending-dose study of bms-791325, a hepatitis c virus (hcv) ns5b polymerase inhibitor, in hcv genotype 1 infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3496-3503

  Sims, Karen D ^a   Lemm, Julie ^a   Eley, Timothy ^a   Liu, Menping ^a   Berglind, Anna ^b   Sherman, Diane ^a   Lawitz, Eric ^c   Vutikullird, Apinya B ^d   Tebas, Pablo ^e   Gao, Min ^a   Pasquinelli, Claudio ^a   Grasela, Dennis M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d WCCT Global   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLABUVIR; PLACEBO; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ANTIVIRUS AGENT; BENZAZEPINE DERIVATIVE; INDOLE DERIVATIVE; INTERFERON; NS-5 PROTEIN, HEPATITIS C VIRUS; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NAUSEA; PHENOTYPE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VOMITING; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; BLOOD; CHEMISTRY; CLASSIFICATION; COHORT ANALYSIS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HALF LIFE TIME; HEPACIVIRUS; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BENZAZEPINES; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HALF-LIFE; HEPACIVIRUS; HEPATITIS C; HUMANS; INDOLES; INTERFERONS; MALE; MIDDLE AGED; PHENOTYPE; RNA REPLICASE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84901289997     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02579-13     Document Type: Article

References (25)

1. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int. 29:74-81. http://dx.doi.org/10.1111/j.1478-3231.2008.01934.x.
2. World Health Organization. 2012. Prevention and control of viral hepatitis infection: framework for global action. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/hepatitis/GHP-framework.pdf. Accessed 5 September 2013.
3. European Association for the Study of the Liver. 2011. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 55:245-264. http://dx.doi.org/10.1016/j.jhep.2011.02.023.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374. http://dx.doi.org/10.1002/hep.22759.
5. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401. http://dx.doi.org/10.1038/nature08309.
6. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis C Cohort Study, Swiss HIV Cohort Study. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338-1345. http://dx.doi.org/10.1053/j.gastro.2009.12.056.
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-Alpha and ribavirin therapy. Nat. Genet. 41:1100-1104. http://dx.doi.org/10.1038/ng.447.
8. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc-Cone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593. http://dx.doi.org/10.1056/NEJMoa0808010.
9. Talal AH, Lafleur J, Hoop R, Pandya P, Martin P, Jacobson I, Han J, Korner EJ. 2013. Absolute and relative contraindications to pegylatedinterferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment. Pharmacol. Ther. 37:473-481. http://dx.doi.org/10.1111/apt.12200.
10. Ghany M, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444. http://dx.doi.org/10.1002/hep.24641.
11. Pawlotsky JM. 2011. The results of phase III clinical trial with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140:746-754. http://dx.doi.org/10.1053/j.gastro.2011.01.028.
12. Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DL, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M. 2009. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitisCvirus. Hepatology 49:745-752. http://dx.doi.org/10.1002/hep.22717.
13. Legrand-Abravanel F, Nicot F, Izopet J. 2010. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs 19:963-975. http://dx.doi.org/10.1517/13543784.2010.500285.
14. Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi JP, Storer R, Gosselin G. 2006. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2-C-methylcytidine. J. Med. Chem. 49:6614-6620. http://dx.doi.org/10.1021/jm0603623.
15. Lemm JA, Liu M, Gentles RG, Ding M, Voss S, Pelosi LA, Wang Y-K, Rigat KL, Mosure KW, Bender JA, Knipe JO, Colonno R, Meanwell NA, Kadow JF, Santone KS, Roberts SB, Gao M. 2014. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 58:3485-3495. http://dx.doi.org/10.1128/AAC.02495-13.
16. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA. 2012. Effect on hepatitis C virus replication of combinations of direct-Acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob. Agents Chemother. 56:5230-5239. http://dx.doi.org/10.1128/AAC.01209-12.
17. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De Francesco R, Migliaccio G. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77: 13225-13231. http://dx.doi.org/10. 1128/JVI.77.24.13225-13231.2003.
18. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489. http://dx.doi.org/10.1126/science.7824947.
19. Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefebvre S, Thauvette L, Gauthier J, Goulet S, Poupart MA, Beaulieu PL. 2005. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 280:39260-39267. http://dx.doi.org/10.1074/jbc.M506407200.
20. Tomei L, Altamura S, Paonessa G, De Francesco R, Migliaccio G. 2005. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir. Chem. Chemother. 16:225-245.
21. Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arastéh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Böcher W, Steffgen J. 2012. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J. Hepatol. 57:39-46. http://dx.doi.org/10.1016/j.jhep.2012.02.015.
22. McPhee F, Falk P, Lemm J, Liu M, Kirk M, Hernandez D, Cooney E, Hughes EA, Gao M. 2012. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-Alfa and ribavirin. J. Hepatol. 56(Suppl 2):S473. (Abstract.) http://dx.doi.org/10.1016/S0168-8278(12) 61206-9.
23. de Bethune MP. 2010. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 85:75-90. http://dx.doi.org/10.1016/j.antiviral.2009.09.008.
24. Tatum HA, Thuluvath PJ, Lawitz E, Martorell C, DeMicco M, Cohen S, Rustgi V, Ravendhran N, Ghalib R, Hanson J, Zamparo J, Yang R, Hughes EA, Cooney E. 2012. A phase 2a study of BMS-791325, an NS5B polymerase inhibitor, with peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C virus infection. J. Hepatol. 56(Suppl 2):S460. (Abstract.) http://dx.doi.org/10.1016/S0168-8278(12)61175-1.
25. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. 2014. Efficacy of an interferon-And ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146:420-429. http://dx.doi.org/10.1053/j.gastro.2013.10.057.